Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-445 triple-combination study in adults with cystic fibrosis
NL-OMON47700Phase 2Active, not recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of elexacaftor, tezacaftor, ivacaftor and deutivacaftor in cystic fibrosis (CF) (4 arms), sponsored by Vertex Pharmaceuticals. Primary endpoints: Safety and tolerability, Absolute change in ppFEV1 and 2 more. Started Oct 2017; status: active, not recruiting.
02
Drugs
elexacaftortezacaftorivacaftordeutivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NL-OMON47700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47700.